expert reaction to news reports that the Oxford/AZ vaccine gives limited protection against mild disease caused by the South African variant of SARS-CoV-2

SEMrush

There have been news reports that the Oxford/AstraZeneca COVID-19 vaccine provides limited protection against mild disease caused by the SARS-CoV-2 variant first detected in South Africa, 501Y.V2.

 

Prof Peter Openshaw, Professor of Experimental Medicine at Imperial College London, said:

“The information we have is very limited, but the trial seems to have been restricted to HIV negative younger people (mean age 31), about 1000 in the placebo arm and 1000 in the active vaccine group. In this age group and with these numbers, the effect on severe disease is going to be hard to estimate. Without seeing results in detail, it isn’t possible be sure how firm these conclusions are.

“However, if the press reports are correct it does seem of concern that protection against disease was not shown. The findings of the Novavax vaccine trial of 60% efficacy in the prevention of disease of any severity in HIV negative volunteers in South Africa might also suggest that vaccines will need to be updated in line with emerging mutations of the virus.

“Although the most obvious explanation for the apparent reduced efficacy is the emergence of variants, the role of anti-adenovirus cross-reactive immunity should also be examined. The Oxford/AZ vaccine is a disabled simian adenovirus and should not be affected by prior exposure to other adenoviruses, but this needs checking.

“Vaccines that are effective against the more severe forms of disease may not affect milder forms, so there is optimism that severe disease will still be prevented by vaccines based on the original spike protein despite mutations. In addition, many of the vaccines now proven to be effective can be relatively easily redesigned to express emerging forms of the viral protein.”

 

Prof Anthony Harnden, Deputy Chair of Joint Committee on Vaccination and Immunisation, said:

“Evidence suggests the Oxford AZ vaccine protects against disease caused by the predominant Covid variants circulating in the UK. It remains highly likely that the vaccine will also protect against severe disease caused by the South African variant.”

 

 

eg. https://www.bbc.co.uk/news/uk-55967767

https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36 

 

 

Declared interests

None received

[automaticbacklinks]